Q: Why are oncology protocols so complicated?
Cancer itself is a complex disease, and pretending otherwise would be the real problem. Each treatment protocol aims to manage a disease that exhibits varying behaviors among patients, even when the diagnosis appears identical on paper. Even with the same tumor type and treatment regimen, the underlying biology can be completely different. Therefore, what is documented on paper is not just “how to administer a drug.” It is an attempt to anticipate the variability, disease behavior, prior treatments, organ function, and molecular drivers, all simultaneously.
Early-phase trials are not just asking if a treatment works; they’re also trying to determine the safe dose, understand the long-term effects of toxicity, assess interactions with other therapies, identify valuable signals, and distinguish between noise. This requires stringent eligibility criteria, rigorous safety monitoring, and dose modification rules that may seem overly cautious. However, these measures are based on invaluable lessons learned from challenging experiences.
Another aspect that people often overlook is the role of protocols in standardizing decision-making across numerous sites, investigators, and healthcare systems. What may seem “obvious” to one physician might not be to another. Therefore, we carefully document everything, sometimes to an excessive level of detail, because consistency is crucial when interpreting safety and efficacy across a global study.
Key takeaway: Oncology protocols appear complex because they carry the weight of uncertainty, variability, and risk simultaneously. They are not merely instructions but rather guardrails built from experience, trying to make unpredictable biology just structured enough to study safely.
Question for you: What’s one part of oncology protocols you’ve found unnecessarily complex, or, on the flip side, something you think isn’t detailed enough?